Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators. De Caterina R, et al. Among authors: laeis p. J Cardiovasc Med (Hagerstown). 2019 Feb;20(2):97-104. doi: 10.2459/JCM.0000000000000737. J Cardiovasc Med (Hagerstown). 2019. PMID: 30540648 Free article.
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Kerschnitzki M, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators. De Caterina R, et al. Among authors: laeis p. BMC Cardiovasc Disord. 2019 Jul 12;19(1):165. doi: 10.1186/s12872-019-1144-x. BMC Cardiovasc Disord. 2019. PMID: 31299906 Free PMC article.
The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.
De Caterina R, Agnelli G, Laeis P, Unverdorben M, Rauer H, Wang CC, Nakamura M, Chiu KM, Reimitz PE, Koretsune Y, Chen C, Thee U, Kaburagi J, Kim YH, Choi WI, Yamashita T, Cohen A, Kirchhof P. De Caterina R, et al. Among authors: laeis p. Clin Cardiol. 2019 Dec;42(12):1147-1154. doi: 10.1002/clc.23279. Epub 2019 Oct 25. Clin Cardiol. 2019. PMID: 31650560 Free PMC article.
Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study.
Colonna P, von Heymann C, Santamaria A, Saxena M, Vanassche T, Wolpert D, Laeis P, Wilkins R, Chen C, Unverdorben M. Colonna P, et al. Among authors: laeis p. Clin Cardiol. 2020 Jul;43(7):769-780. doi: 10.1002/clc.23379. Epub 2020 May 14. Clin Cardiol. 2020. PMID: 32406557 Free PMC article.
Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.
de Groot JR, Weiss TW, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Waltenberger J, Steffel J, Levy P, Bakhai A, Zierhut W, Laeis P, Manu MC, Reimitz PE, De Caterina R, Kirchhof P. de Groot JR, et al. Among authors: laeis p. Eur Heart J Cardiovasc Pharmacother. 2021 Apr 9;7(FI1):f30-f39. doi: 10.1093/ehjcvp/pvaa079. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 32790837 Free PMC article.
Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.
Vranckx P, Valgimigli M, Eckardt L, Lewalter T, Unikas R, Marin F, Schiele F, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Tijssen J, Goette A. Vranckx P, et al. Among authors: laeis p. Eur Heart J. 2020 Dec 14;41(47):4497-4504. doi: 10.1093/eurheartj/ehaa617. Eur Heart J. 2020. PMID: 32860041 Free PMC article. Clinical Trial.
Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study.
Unverdorben M, von Heymann C, Santamaria A, Saxena M, Vanassche T, Jin J, Laeis P, Wilkins R, Chen C, Colonna P. Unverdorben M, et al. Among authors: laeis p. BMC Cardiovasc Disord. 2020 Dec 1;20(1):504. doi: 10.1186/s12872-020-01766-w. BMC Cardiovasc Disord. 2020. PMID: 33256590 Free PMC article.
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Van Mieghem NM, Unverdorben M, Hengstenberg C, Möllmann H, Mehran R, López-Otero D, Nombela-Franco L, Moreno R, Nordbeck P, Thiele H, Lang I, Zamorano JL, Shawl F, Yamamoto M, Watanabe Y, Hayashida K, Hambrecht R, Meincke F, Vranckx P, Jin J, Boersma E, Rodés-Cabau J, Ohlmann P, Capranzano P, Kim HS, Pilgrim T, Anderson R, Baber U, Duggal A, Laeis P, Lanz H, Chen C, Valgimigli M, Veltkamp R, Saito S, Dangas GD; ENVISAGE-TAVI AF Investigators. Van Mieghem NM, et al. Among authors: laeis p. N Engl J Med. 2021 Dec 2;385(23):2150-2160. doi: 10.1056/NEJMoa2111016. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449183 Clinical Trial.
41 results